title: Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
abstract: Single photon emission tomography (SPET) permits the in vivo measurements of regional cerebral radioactivity in the human brain following the administration of compounds labeled with photon-emitting isotopes. According to our SPET findings of a reduced binding of [123I]labeled (S)-2-hydroxy-3-iodo-6-methoxy-([1-ethyl-2-pyrrolidinyl]methyl) benzamide (IBZM) (a highly selective CNS D2 dopamine receptor ligand) to D2 dopamine receptors in striatal structures in untreated patients with nocturnal myoclonus syndrome (NMS) it seemed to be of interest to investigate whether there are changes in D2 receptor binding under dopamine replacement therapy or not. We studied the uptake and distribution of [123I]IBZM before and in the course of dopamine replacement therapy in four patients with severe insomnia caused by a nocturnal myoclonus syndrome (NMS). We found an increase of the IBZM binding to D2 receptors in the course of treatment, which was associated with an improvement of sleep quality. Reasons for this are discussed. The [123I]IBZM SPET technique in conclusion offers an intersting tool for in vivo investigations of functional changes in the dopaminergic neurotransmitter system in longitudinal studies.
authors.affiliation: Department of Psychiatry, Georg August University, Göttingen, Federal Republic of Germany.
authors.forename: J
authors.initials: J
authors.lastname: Staedt
authors.forename: G
authors.initials: G
authors.lastname: Stoppe
authors.forename: A
authors.initials: A
authors.lastname: Kögler
authors.forename: H
authors.initials: H
authors.lastname: Riemann
authors.forename: G
authors.initials: G
authors.lastname: Hajak
authors.forename: D L
authors.initials: DL
authors.lastname: Munz
authors.forename: D
authors.initials: D
authors.lastname: Emrich
authors.forename: E
authors.initials: E
authors.lastname: Rüther
mesh_terms: D000368:Aged; D001549:Benzamides / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging*; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D015259:Dopamine Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy / Q000378:metabolism*; D017286:Polysomnography; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001549:Benzamides; D015259:Dopamine Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D007980:Levodopa; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D004298:Dopamine